Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India

  • Pankaj Malhotra
  • Uday Yanamandra
  • Alka Khadwal
  • Gaurav Prakash
  • Deepesh Lad
  • Arjun D. Law
  • Harshit Khurana
  • M. U. S. Sachdeva
  • Praveen Bose
  • Reena Das
  • Neelam Varma
  • Subhash Varma
Original Article


Autologous stem cell transplantation (ASCT) is considered as standard of care in patients with multiple myeloma (MM) patients aged 65 years or younger. We analyzed data of 94 patients of plasma cell dyscrasias who underwent 95 autologous transplants at our institute from October 2003 to Aug 2016. Other than 76 patients of newly diagnosed multiple myeloma, we also transplanted two patients of POEMS syndrome, two patients of plasma cell leukemia, three patients of concurrent light chain deposition disease, three patients of multifocal plasmacytomas, and eight patients of isolated light chain myeloma. One patient underwent transplant twice. The median age of patients was 53 years (range 21–65). The average interval between diagnosis and transplant was 10.51 ± 5.42 months. The predominant stage in the study cohort was ISS-III. IgG kappa was the commonest subtype of plasma cell dyscrasia (27.9%) followed by IgG lambda (16.27%). Renal involvement was seen in 25% patients at the time of transplantation. Following chemotherapy, 42% patients were in CR, 39% in VGPR, 5% had PR and 14% had progressive disease at the time of transplantation. All patients were conditioned with melphalan (dose 120–200 mg/m2) except for one who received an additional bortezomib for his second transplant. The mean time to neutrophil and platelet engraftment was 11.09 ± 1.82 and 12.69 ± 4.55 days respectively. Mucositis was noted in all patients (grade 3 in 37.5% patients). The median PFS (biochemical) was 55.8% and PFS (clinical) was 76.7% at 6.5 years. Thirteen percent of the transplanted patients succumbed to their illness of which three patients died within 30 days of transplant. Median OS was 76.7% at 6.5 years. ASCT is a feasible option for MM in India and the results are comparable.


ASCT  Myeloma  Real World  Transplant  Autologous 


Compliance with Ethical Standards

Conflict of interest

All Authors declare that they have no conflict of interest.

Human and Animal Rights

This research is involving human participants.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962–2972CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kumar L, Verma R, Radhakrishnan VR (2010) Recent advances in the management of multiple myeloma. Nat Med J India 23(4):210–218Google Scholar
  3. 3.
    Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR et al (1987) Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66(1):55–62CrossRefPubMedGoogle Scholar
  4. 4.
    Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95(12):4008–4010PubMedGoogle Scholar
  5. 5.
    Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335(2):91–97CrossRefPubMedGoogle Scholar
  6. 6.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883CrossRefPubMedGoogle Scholar
  7. 7.
    Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95(1):7–11PubMedGoogle Scholar
  8. 8.
    Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transpl 13(2):183–196CrossRefGoogle Scholar
  9. 9.
    Lévy V, Katsahian S, Fermand JP, Mary JY, Chevret S (2005) A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine 84(4):250–259CrossRefPubMedGoogle Scholar
  10. 10.
    Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G et al (2014) Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis 6(1):e2014046CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V (2009) High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transpl 43(6):481–489CrossRefGoogle Scholar
  12. 12.
    Nath UK, Chakrabarti P, Ray SS, Chaudhuri U (2010) Starting autologous transplantation in a non-hepa filtered unit in a medical college with severe resource constraints. Indian J Hematol Blood Transfus 26(4):172Google Scholar
  13. 13.
    Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346CrossRefPubMedGoogle Scholar
  14. 14.
    Ashok P, Mani K, Sadashivudu G, Srinivas ML (2015) Study of quality of life in multiple myeloma patients after autologous stem cell transplantation. Indian J Hematol Blood Transf 1:S67–S68Google Scholar
  15. 15.
    Gupta S, Kumar L, Raju GM, Kochupillai V, Shukla DK (2000) Autologous bone marrow/stem cell transplantation: initial experience at a north Indian referral centre. Natl Med J India 13(2):61–66PubMedGoogle Scholar
  16. 16.
    Gupta A, Kumar L, Dabkara D, Gupta D, Sharma O, Sreeniwas V (2009) Multiple myeloma: autologous stem cell transplantation versus conventional chemotherapy—a retrospective age and stage matched analysis. J Clin Oncol 1:7041Google Scholar
  17. 17.
    Lu J, Hou J, Liu K-Y, Parmar S, De La Fuente A, Andersson B et al (2016) Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th international hematologic malignancies conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1534–1538CrossRefPubMedGoogle Scholar
  18. 18.
    Prakash Yadav S, Kalra M, Sachdeva A, Dinand V, Parashar N, Kohli S et al (2009) The experience of hematopoietic stem cell transplantation from an emerging centre in north India. In: Blood conference: 51st annual meeting of the American society of hematology, ASH New Orleans, LA United States Conference Start, vol 114, no. 22Google Scholar
  19. 19.
    Sagar TG, Rathinam K, Trivadi G, Rejiv R, Prasanth G (2015) Outcomes in multiple myeloma post high dose chemotherapy and autologous stem cell transplantation-single institute experience. Indian J Hematol Blood Transf 1:S65Google Scholar
  20. 20.
    Kumar L, Malik PS, Prakash G, Prabu R, Radhakrishnan V, Katyal S et al (2011) Autologous hematopoietic stem cell transplantation-what determines the outcome: an experience from North India. Ann Hematol 90(11):1317–1328CrossRefPubMedGoogle Scholar
  21. 21.
    Kumar L (2013) Autologous stem cell transplant for multiple myeloma. Indian J Hematol Blood Transf 29(4):243Google Scholar
  22. 22.
    Dolai TK, Kumar M, Kumar Mandal P, Saha S, Bagchi B, Panigrahi A et al (2013) Auto-SCT for myeloma patients in non-HEPA filtered room: initial experience of a tertiary care center. Leuk Lymphoma 54:26Google Scholar
  23. 23.
    Kaul E, Kothari S, Sharma SK, Dhamija M, Kharya G, Khandelwal V et al (2015) Day 4 peripheral blood stem cell collection in myeloma patients is feasible and cost-effective in a majority of patients. Clin Lymphoma Myeloma Leuk 15:e169–e170CrossRefGoogle Scholar
  24. 24.
    Kumar L, Cyriac SL, Tejomurtula TV, Bahl A, Biswas B, Sahoo RK et al (2013) Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors. Clin Lymphoma Myeloma Leuk 13(1):32–41CrossRefPubMedGoogle Scholar
  25. 25.
    Shah CA, Karanwal A, Desai M, Pandya M, Shah R (2015) Hematopoietic stem-cell transplantation in the developing world: experience from a center in Western India. J Oncol 2015:710543CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bagal B, Jain H, Dangi U, Sengar M, Kannan S, Rangarajan V et al (2014) Pretransplant PET positivity predicts early relapse with poor outcome in patients of multiple myeloma undergoing autologous stem cell transplantation. Blood 124(21):3997Google Scholar
  27. 27.
    Mukhopadhyay A, Gupta P, Basak J, Chakraborty A, Bhattacharyya D, Mukhopadhyay S et al (2012) Stem cell transplant: an experience from eastern India. Indian J Med Paediatr Oncol 33(4):203–209CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Aggarwal S, Bhalla A, Khatri SL, Anand Simar S, Bhargava M, Saran R (2011) Bortezomib plus dexamethasone as induction treatment followed by autologous peripheral blood stem cell transplantation in patients with multiple myeloma: a study from india. In: Blood conference: 53rd annual meeting of the American society of hematology, ASH, vol 118, no. 21Google Scholar
  29. 29.
    Bagal BP, Khattry N, Dongre A, Kanan S, Menon H, Sengar M et al (2012) Outcomes of autologous stem cell transplant (ASCT) in multiple myeloma from a tertiary cancer center in India. J Clin Oncol Conf 30(15 SUPPL. 1):e17003Google Scholar
  30. 30.
    Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A et al (2014) Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med 3(4):939–946CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Boya RR, Bakhshi S, Gogia A, Sahoo RK, Kumar L (2015) Prediction of poor mobilization of Peripheral Blood Stem Cells (PBSC) with G-CSF alone, in multiple myeloma (MM) patients undergoing autologous transplantation: a prospective study. Clin Lymphoma Myeloma Leuk 15:e171–e172CrossRefGoogle Scholar
  32. 32.
    Reddy R, Bakhshi S, Sharma A, Sahoo R, Gogia A, Malik PS et al (2015) Poor mobilization of peipheral blood stem cells (PBSC) in patients undergoing autologous stem cell transplantation (ASCT): a prospective study. J Clin Oncol Conf 33(15 SUPPL. 1):e18013Google Scholar
  33. 33.
    Munker R, Shi R, Nair B, Devarakonda S, Cotelingam JD, McLarty J et al (2015) The Shreveport myeloma experience: survival, risk factors and other malignancies in the age of stem cell transplantation. Acta Haematol 135(3):146–155CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  • Pankaj Malhotra
    • 1
  • Uday Yanamandra
    • 2
  • Alka Khadwal
    • 1
  • Gaurav Prakash
    • 1
  • Deepesh Lad
    • 1
  • Arjun D. Law
    • 3
  • Harshit Khurana
    • 4
  • M. U. S. Sachdeva
    • 5
  • Praveen Bose
    • 5
  • Reena Das
    • 5
  • Neelam Varma
    • 5
  • Subhash Varma
    • 1
  1. 1.Clinical Haematology Division, Department of Internal MedicinePostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  2. 2.Department of Haematology and Stem Cell TransplantArmy Hospital (Research and Referral)DelhiIndia
  3. 3.Division of Medical Oncology and Haematology, Princess Margaret Cancer CentreUniversity Health Network, University of TorontoTorontoCanada
  4. 4.Department of Internal MedicineCommand Hospital (Air Force)BangaloreIndia
  5. 5.Department of HaematologyPostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations